Ziopharm Oncology to Report Second Quarter 2020 Financial Results and Host a Conference Call and Webcast on August 6, 2020

Rhea-AI Summary

Ziopharm Oncology (Nasdaq: ZIOP) announced a conference call and webcast scheduled for August 6, 2020, at 4:30 pm EDT. The call will provide a corporate update and discuss financial results for Q2 2020, ending June 30, 2020. Investors can access the call by dialing designated numbers in the U.S. and internationally, with a passcode provided. The live webcast will be available on the company’s website, allowing for a subsequent archived recording for two weeks. Ziopharm specializes in immuno-oncology with its non-viral Sleeping Beauty platform for T-cell therapies.

Positive

• Upcoming conference call to discuss Q2 2020 financial results may provide insights into company performance.
• The company’s focus on developing innovative immuno-oncology treatments could attract investor interest.

Negative

• None.

BOSTON, July 28, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq: ZIOP), today announced the Company will host a conference call and webcast on Thursday, August 6, at 4:30 pm EDT to provide a corporate update and discuss financial results for the second quarter ended June 30, 2020.

The call can be accessed by dialing 1-877-451-6152 (U.S. and Canada) or 1-201-389-0879 (international). The passcode for the conference call is 13706729. To access the live webcast or the subsequent archived recording, visit the “Investors” section of the Ziopharm website at www.ziopharm.com. The webcast will be recorded and available for replay on the Company’s website for two weeks.

About Ziopharm Oncology, Inc.
Ziopharm Oncology is an immuno-oncology company focused on developing end-to-end cost-effective solutions using its non-viral Sleeping Beauty platform for T-cell receptor (TCR) and chimeric antigen receptor (CAR) T-cell therapies and immune-stimulating gene therapy with Controlled interleukin 12 (IL-12). The Sleeping Beauty platform genetically modifies T cells with DNA plasmids to express TCRs to target neoantigens inside and outside hotspots for solid tumors and CAR to target CD19 for blood cancers using the Company’s “Rapid Personalized Manufacturing” to produce and release CAR-T as soon as the day after gene transfer. The Sleeping Beauty platform is being advanced in collaboration with the National Cancer Institute, The University of Texas MD Anderson Cancer Center and Eden BioCell. The Company is also developing its Controlled IL-12 platform, or Ad-RTS-hIL-12 plus veledimex, as monotherapy and in combination with immune checkpoint inhibitors to treat brain cancer, including in collaboration with Regeneron Pharmaceuticals.

Ziopharm Oncology Contact:
Chris Taylor
VP, Investor Relations and Corporate Communications
T: 617.502.1881
E: ctaylor@ziopharm.com

FAQ

When is the Ziopharm Oncology conference call for Q2 2020 results?

The conference call is scheduled for August 6, 2020, at 4:30 pm EDT.

How can I access the Ziopharm Oncology conference call?

The call can be accessed by dialing 1-877-451-6152 for U.S. and Canada or 1-201-389-0879 internationally, with passcode 13706729.

Where can I find the webcast for the Ziopharm Oncology conference call?

The live webcast can be accessed on the company's website in the 'Investors' section.

What is the focus of Ziopharm Oncology's research?

Ziopharm Oncology focuses on developing immuno-oncology treatments using its non-viral Sleeping Beauty platform.

What collaborations does Ziopharm Oncology have?

The company collaborates with the National Cancer Institute and The University of Texas MD Anderson Cancer Center.